GSK is set to gain exclusive rights to first-in-class oral antifungal Brexafemme (ibrexafungerp) for treating vulvovaginal candidiasis (VVC) and recurrent VVC (RVVC) from...
26.08.2016
- With plenty of cash still in the kitty after a failed attempt last April to buy Allergan for $160 million and move its headquarters to Ireland, Pfizer continues to pound the...
